Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
#3PRI RANKED
Most Cited Paper
in Immunotherapy and Immune Responses
18 Months Post-Publication
Class of 2026
“Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026/
Topics
CAR-NK cells · CD19 CAR T-cell therapy · cord blood-derived NK cells · IL-15 · allogeneic CAR T cells · CD19+ B cell malignancies · phase 1/2 trial · Objective response rate (ORR) · progression-free survival · CAR-NK cell persistence · cytokine release syndrome · graft-versus-host disease · cord blood unit selection · nucleated red blood cell count · collection-to-cryopreservation time · effector-related gene signature · hypoxia stress response · cellular stress programs · mouse xenograft models · donor selection criteria
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026. https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026. Accessed 2026-07-20. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459